



Version of attached le:
Published Version
Peer-review status of attached le:
Peer-reviewed
Citation for published item:
Noorani, Tehseen and Martell, Jonny (2021) 'New Frontiers or a Bursting Bubble? Psychedelic Therapy
Beyond the Dichotomy.', Frontiers in psychiatry., 12 .
Further information on publisher's website:
https://doi.org/10.3389/fpsyt.2021.727050
Publisher's copyright statement:
Copyright c© 2021 Noorani and Martell. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-prot purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
https://dro.dur.ac.uk
OPINION
published: 10 September 2021
doi: 10.3389/fpsyt.2021.727050













This article was submitted to
Psychopathology,
a section of the journal
Frontiers in Psychiatry
Received: 17 June 2021
Accepted: 17 August 2021
Published: 10 September 2021
Citation:
Noorani T and Martell J (2021) New
Frontiers or a Bursting Bubble?




New Frontiers or a Bursting Bubble?
Psychedelic Therapy Beyond the
Dichotomy
Tehseen Noorani 1* and Jonny Martell 2
1Department of Anthropology, Durham University, Durham, United Kingdom, 2Centre for Psychedelic Research, Imperial
College London, London, United Kingdom
Keywords: psychedelic therapy, bubble, opportunity, psychedelics, hallucinogens, regulation
INTRODUCTION
The publication in April 2021 of the Imperial College London Phase II study investigating
the efficacy of psilocybin-assisted therapy vs. escitalopram for depression reported differences
in the primary outcome measure (the QIDS-SR16) between experimental and control arms as
statistically insignificant (1). However, secondary measures of depression, and other relevant
measures (see Appendix), favored psilocybin to escitalopram. Soon thereafter, a range of expert
commentaries offered interpretations, including that the researchers were unfortunate in their
choice of pre-registered primary outcome, the trial was underpowered perhaps revealing an
overconfidence in designing the study, and the limitations of depression rating measures to capture
the return of positive mood and well-being.
Partially in response to these publications, discussions in research and online communities
have grown around the over-hyping of psychedelic treatments, bringing into focus concerns over
psychedelic therapy trial methodology [for a peer-reviewed critique, see (2)]. This opinion piece
explores these concerns to propose a response to this special issue’s question, “Can Psychedelic
Therapies Open a New Frontier in Mental Healthcare (Or Will the Bubble Burst)?” Drawing on
our experiences of working within psychedelic clinical trials and NHS psychiatry, we offer here a
deflationary answer to this question, suggesting both will occur and outlining some of the facets,
stakes and opportunities entailed.
PART I: THE BURSTING BUBBLE
The enthusiastic reception and excitement over the potential of psychedelics in academic, medical,
public, and even political arenas is buttressed by the growing call for new psychiatric treatments,
concerns over the long-term prescription of antidepressants to growing patient numbers without
a concomitant reduction in psychiatric morbidity, and increasing evidence of withdrawal effects
(3, 4). We define the “psychedelic therapy bubble” as an overestimation of its promise that is not
justified by what is and can be known about its therapeutic potential. Coining the term promissory
science, Davis and Abraham describe how,
“in connection with the manufacturer’s promotion of apparently hopeful clinical trial results in the lead
up to a new drug application for marketing approval...both the hopeful results and the novelty of the
new drug’s hypothesized mechanism of therapeutic efficacy may be elevated to great clinical significance
to an expectant medical profession, patient population and stock market” [(5), p.268] [see also (6, 7)].
Understanding the psychedelic therapy bubble in terms of promissory science highlights the
feedback loops whereby inflated expectations are themselves shaping psychedelic therapy’s
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potential (8). Economically, the bubble sustains sufficient
initial investments to offset the direct and infrastructural costs
of bringing psychedelic therapies to market. Consequently,
commercial imperatives of efficiency, standardization, and
scalability are steering ongoing research. Advocates of
these processes argue that this is either appropriate or at
least necessary, in order to re-invigorate psychiatry’s tired
pharmacopeia (9). Culturally, the success of psychedelic therapy
has been steered by actors seeking redemption for psychedelic-
assisted and related healing practices in the wake of psychedelic
prohibition at the end of the 1960s, and the researchers among
them have brought particular interpretive frameworks for
understanding the nature and value of psychedelic experiences.
This includes the foregrounding of the therapeutic value of the
mystical-type experience, which has begun to be problematized
from various quarters as overly simplistic [e.g., (10)].
The concern with psychedelic therapy being a bubble that may
burst is sometimes reduced to a warning against a repeat of drug
prohibitionist laws and policies [e.g., (11)]. Yet the more colorful
narrative of psychedelic research as a casualty in Nixon’s fight
against the counterculture has in recent years been tempered by
historical investigation into the effects of an impasse between
paradigms for conducting psychedelic therapy research and the
growing imperatives of standardized randomized controlled trial
(RCT) designs (12, 13). Moreover, today’s situation is different
in key ways: firstly, scholars have documented how medical
professionals, regulators, and patient groups have pushed for
“pragmatic” and “adaptive” trial designs in the intervening
decades (14). Secondly, today’s psychedelic clinical researchers
are self-consciously aware of, and keen to prevent, a return to
psychedelic prohibition, carefully proffering a “sober objectivity,”
and emphasizing psychedelics as therapeutic agents as opposed
to subversive agents of social and political change (15). Thirdly,
we suggest psychedelic therapy is well-suited to the growing calls
for psychiatry to be more oriented to the relational (16).
Nevertheless, bubbles burst, and we offer four axes along
which to consider this in relation to psychedelic therapies. Firstly,
critiques of psychedelic therapy trial publications have warned of
common features of the RCTs that are likely to be inflating effect
sizes: participant self-selection, stringent screening procedures,
small sample sizes, and difficulty in maintaining blinding in
research trials (2). Secondly, as the therapies gain legitimacy,
the psychedelic research community is itself changing. Until
recently, this community has comprised researchers who were
willing to accept the professional ramifications of working
in a stigmatized area. While the early advocates of any new
treatment can be expected to be enthusiastic, the interaction
effects of any researcher bias with psychedelics’ sensitivity to the
context of their use would contribute especially large outcome
confounders, leading to limited replication of the early findings.
Thirdly, we should anticipate a growth in adverse outcomes as
the hype grows, the participant/patient pool is widened, and
psychedelic therapies are provided in more streamlined ways.
Increasingly diverse patient populations hopeful of being cured
will experience rocky “landings” post-treatment, the cost of
which will be borne downstream of trial analysis end points,
thereby falsely inflating favorable health economic calculations.
And fourthly, we are yet to understand the nature and extent of
ethical dilemmas that will emerge. For example, with regards to
“false memory syndrome,” the complexity of working with the
veracity of unmediated knowledge has recently been explored
(17), posing a challenge for manualized and protocolized therapy
training programs.
PART II: NEW FRONTIERS
Recognizing that psychedelic therapy is a bubble that will burst
should not be taken to mean that psychedelics do not offer
“new frontiers.” On the contrary, we outline four areas below in
which psychedelic therapy has the potential to transform mental
healthcare, even if it is not approved and mainstreamed to the
extent currently anticipated.
Novel Compounds
Psychedelic research has stimulated interest in a trove of new
psychedelic-inspired compounds (for example, see MagicMed
Industries Inc’s PsybraryTM), with differing pharmacological and
risk profiles. We can expect the effects they produce to range
from therapeutic to toxic and psychoactive to non-psychoactive.
With the proliferation of these compounds, we anticipate a
growing discussion about the necessity of the psychedelic
experience for therapeutic gain [e.g., (18, 19)]. Additionally, the
development of “neutralization technologies” for terminating the
psychedelic experience and drug administration through novel
target-controlled intravenous infusion techniques (20) suggest
to us that therapeutic practices will be developed that combine
both “shutting down” and “opening up” to offer new options
for experiential manipulation, in line with the growing call for
personalized medicine.
Psychedelic Therapy as Driving Interest in
Suggestion
Psychedelic therapy trials are generating data we suggest
could fruitfully be conceptualized through the framework
of the sensitivity of therapeutic altered states to suggestion.
This connects several literatures: a tradition of psychedelic
research that proposes the drugs produce states of heightened
suggestibility against a longer historical interest in hypnosis
(21–24); psychedelics as psychoplastogens, increasing cognitive
and emotional flexibility (25–27)); the field of placebo studies
(28–30); ritual theory (31, 32) and the study of “common factors”
across psychotherapies (33) alongside other process-oriented
research into psychological change. By bringing these literatures
into a fuller encounter, we imagine a range of conceptual
distinctions, methodological considerations, and theories,
animating new directions for psychedelic therapy research.
Considering the above literatures, it would be timely to bring
together psychedelic researchers and experts in these related
areas, to identify trial designs and interpretive frameworks
that support mutually fruitful lines of inquiry. Interdisciplinary
research could reveal the processes by which the psychedelic
experience may be “baking in” a particular message or self-
reorientation that has been primed or reinforced by the other
study components. Without wanting to foreclose what such
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conversations will open up, we are particularly interested in two
avenues of inquiry: firstly, more fully measuring the expectations
held by participants at different stages of the intervention would
reveal more than potential confounds within trials—it could
teach us about the looping effects of the bubble itself, by
indexing how trials are themselves differentially emplaced within
a timeline of the evolving hype around psychedelic therapies.
Secondly, a fuller engagement with placebo studies suggests the
need to consider more fully the role of uncertainty, hesitation,
and doubt in healing through psychedelic therapy (31, 34), and
how these are cultivated through drug-set-setting configurations
that offer the opportunity to “[traffic] in human possibilities
rather than in settled certainties” (35). Reflections on the history
of placebo studies may also caution against reprising politically
and ethically fraught attempts to identify the suggestible “type”
of person (Phoebe Friesen, personal communication). We worry,
however, that such interdisciplinary enquiry is being sidelined in
the rush to approve particular psychedelic therapy packages for
the treatment of particular indications.
The Role of Care
A broad intersecting of psychedelic research and related research
literatures also suggests a deeper valuing of the role of care
structures in psychiatric care writ-large. While the imperative
in placebo-controlled antidepressant trials has been to minimize
the placebo response by limiting patient expectancy and
therapeutic contact (36, 37), this is inverted in the enriched
spaces and care protocols developed for psychedelic therapies
(38). These spaces and protocols challenge the reductionism of
psychopharmacological interventions by drawing attention to
the relational aspects of care, moving from a compartmentalized
focus on symptoms in need of treatment to a more holistic view
of human suffering and the value of meaning-making in health
and wellness. More broadly, the rise of the psychedelic therapy
bubble has contributed to the growing awareness of a wider
ecology of healing practices that center the body, space-making,
and spirituality.
However, the significant opportunities for psychedelic
researchers to refocus psychiatric treatments on enriching
and optimizing relations of care is compromised by industry
pressures, including commercial incentives to foreground
the “drug treatment” model over the crucial (39) but costly
psychotherapeutic work, and a regulatory system designed to
evaluate the administration of drugs as stand-alone treatment
modalities. Emphasizing the relations of care that appear to
us to be key to safe and effective psychedelic therapy will also
require coordination across scales and disciplines. For example,
some psychedelic advocates are beginning to make the economic
case for psychedelic therapies by appealing to the long-term
cost-savings achieved if psychedelic therapies are considered a
curative rather than a palliative care treatment [in relation to
MDMA-assisted psychotherapy, see (40)]. It remains unclear
whether this strategy will persuade healthcare payers.
Regulatory Dynamism
Finally, we suggest that psychedelic therapy research heralds an
opportunity to rethink the regulation of drug research more
broadly, owing to how sensitive psychedelic experiences are to
the context of their use. Some researchers have called for more
detailed measurement of the context of psychedelic therapy in
order to better grasp its therapeutic mechanisms [cf. (38, 41, 42)],
something the growth in survey approaches is endeavoring to
do [e.g., (43)]. We wonder what it might mean to circumscribe
the generalizability of research findings much more narrowly,
acknowledging not simply that there are additional contextual
parameters that need taking into account but that it may not be
possible to determine intervention effects in any general sense,
given the plethora of “experimental contingencies” (2:8) in any
given context.
The need for amore context-sensitive and systematic coupling
of research pre- and post-approval is important. Psychedelic
therapies seek approval based upon safety and efficacy data,
and yet their very approval may affect their efficacy and
safety profiles, as mediated by expectations and understandings
of the substances borne of the evolving bubble that their
hype is generating. Psychedelic therapies also challenge any
easy separation of safety and efficacy, as when, for example,
powerful new meanings and senses of purpose are generated
that are therapeutic, but only with appropriate structures of
support and care. Existing post-approval regulatory landscapes
are poorly equipped to meet the needs of patients for up-
to-date (re-)evaluations of safety and efficacy. Regulators lack
comprehensive and timely data for determining post-approval
safety issues, much less changes in efficacy, and have failed to
enforce the surveillance measures they currently demand of the
pharmaceutical industry (44). The shift in onus of responsibility
to patients and providers to deliver on what is called “post-
marketing surveillance” via reporting systems has largely failed
to deliver, due to under-use and the constraints posed by
imperatives for data anonymization (45).
One logical endpoint of the calls for greater context sensitivity
and the ongoing monitoring of changing safety and efficacy
profiles is in the technically-mediated surveillance of psychedelic
therapy through adjunctive devices and apps, as seen in calls
for the use of ever-more-granular monitoring technologies
in order to adequately power research (46). It remains to
be seen whether such “field approaches” can provide useful
findings. Meanwhile, the normalization of such technologies
raises substantial legal and political concerns, in particular
around the case for reconsidering proprietary rights in relation
to data capture.
DISCUSSION
In this opinion piece we have sought to foster greater critical
discourse around the broader regulatory, cultural and economic
forces shaping psychedelic research. While we have argued for
the need to be attentive to how the psychedelic therapy bubble
is shaping its potential, we end on a note of optimism. In
considering the “bubble” as a public health measure in the
wake of the Covid-19 pandemic, Appleton (47) invites us to
imagine bubbles as affording a protected space in the knowledge
that such a space is temporary. We might then consider
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this moment an opportunity to develop robust methodologies
and alliances across research disciplines and with stakeholder
groups, and to inquire into the most pressing research questions
of psychedelic therapy, before the bubble bursts. For us,
these questions include greater consideration of the role of
community support structures, psychedelic therapy’s long-term
effects, what “safety” and “efficacy” mean amongst different
stakeholder groups, and how best to set up harm reduction
services and infrastructures, all before driving forward the
mass scaling of pre-maturely-rigid formulations of psychedelic
therapy. We recognize that this lies in tension with the
imperative to scale, itself drawing on the language of a growing
“mental health epidemic” and exacerbated by the Covid-19
pandemic. We maintain that by integrating the bubble’s shadow
before it bursts—or at least deflates [cf. (48)]—psychedelic
therapy’s potential to re-invigorate Western psychiatry might be
better realized.
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